Biogen
Prezzo: 200.05Società e modello di business
Biogen is a biotechnology company focused on discovering, developing, and delivering innovative therapies for neurological diseases. Its core products include treatments for multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease. Major business segments encompass neuroscience and rare diseases, with primary revenue sources derived from product sales and royalties. The company is recognized for its research and development efforts in the healthcare sector.
Profilo di investimento
The investment profile of Biogen is more aligned with growth investors, given its focus on innovative therapies and potential for revenue expansion. The stock may appeal to those seeking long-term capital appreciation rather than immediate income. Its moderate volatility suggests a balanced risk approach, suitable for investors with a medium to long-term horizon.
Metriche fondamentali (sperimentale)
- EPS (TTM) — utile per azione degli ultimi 12 mesi, $
- 9.37 OK
- Ricavi QoQ — crescita dei ricavi trimestre su trimestre
- 8.7% ↑
- Sorpresa EPS
- 17.0% meglio del previsto
- Volatilità 20g
- 1.8% stabile
Impatto della previsione
positivoTraccia in portafoglio
Grafico prezzo
| Data | Prima | Dopo | Motivo |
|---|---|---|---|
| 2026-05-28 02:36 | Mantieni | Compra | Strong EPS growth and positive momentum indicators. |
| 2026-05-20 02:36 | Compra | Mantieni | Mixed performance; cautious outlook amid market uncertainty. |
| 2026-05-08 15:04 | — | Compra | Strong EPS growth and positive momentum indicators. |
| Data | Analista | Action | Target | Prezzo allora |
|---|---|---|---|---|
| 2026-06-08 10:32 | Needham | Rating migliorato | — → 255 | 195.34 |
| 2026-05-27 09:42 | RBC Capital | Target alzato | — → 227 | 193.08 |
| 2026-05-15 10:33 | Piper Sandler | Target alzato | 214 → 225 | 191.37 |
Ancora nulla